Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28612285 | 0.90 | SLC2A1 (0.48) | RBP4 | |
| SCHEMBL23826018 | 0.83 | FFAR1 (0.46) | RBP4WDR5FFAR1FFAR4F2 | |
| SCHEMBL16697161 | 0.80 | MET (0.44) | NR1H4F2 | |
| SCHEMBL631819 | 0.76 | DRD2 (0.52) | — | |
| SCHEMBL2089720 | 0.73 | PARP10 (0.50) | WDR5 | |
| SCHEMBL19400195 | 0.73 | CYP4F2 (0.49) | — | |
| SCHEMBL23826968 | 0.73 | GPR119 (0.52) | — | |
| SCHEMBL2811017 | 0.72 | SLC2A1 (0.57) | F2 | |
| SCHEMBL20190433 | 0.71 | NR1H4 (0.60) | NR1H4 | |
| SCHEMBL2999873 | 0.71 | GPR119 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |